Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in refractory/relapsed FLT3-ITD mutant AML
NCT03642236Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Complete Remission Rate. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03642236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642236.